key: cord-0901361-tl7lcd2j
authors: Magnusson, Jesper M.; Silverborn, Martin; Broome, Michael; Riise, Gerdt C.; Dellgren, Göran
title: Long term extracorporeal membrane oxygenation bridge to lung transplant after COVID-19
date: 2021-05-21
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2021.04.092
sha: 6495bef055263890f52eb318f64d125ea12490c1
doc_id: 901361
cord_uid: tl7lcd2j

We report a patient with acute respiratory syndrome coronavirus 2 infection and irreversible lung destruction who underwent successful lung transplantation after 138 days of bridging with extracorporeal membrane oxygenation support. The case exemplifies that lung transplantation might be a possibility after very long-term Coronavirus disease 2019 care, even if the patient is initially unsuitable. Patient consent was acquired before writing the case report.

We report a patient with acute respiratory syndrome coronavirus 2 infection and irreversible lung destruction who underwent successful lung transplantation after 138 days of bridging with extracorporeal membrane oxygenation support. The case exemplifies that lung transplantation might be a possibility after very long-term Coronavirus disease 2019 care, even if the patient is initially unsuitable. Patient consent was acquired before writing the case report.

Coronavirus disease 2019 (COVID-19) is a pandemic disease with a risk for respiratory complications where extracorporeal membrane oxygenation (ECMO) might be initiated in severe cases. ECMO bridge-to-lung transplantation (LTx) is an established option in selected patients 1 . We report a patient with acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) and irreversible lung destruction who underwent successful lung transplantation after 138 days of bridging with ECMO support.

A previously healthy 55-year-old man presented in the emergency ward with fever (39.4 o C), high respiratory rate and a PaO2 of 5.9 kPa despite non-invasive high-flow oxygen. He was intubated and workup showed positive polymerase chain reaction for SARS-CoV-2. After >48h on ventilator, prone ventilation, with FiO2 1.0 with increasing oxygenation difficulties, veno-venous ECMO was initiated.

Cannulas were placed in the right internal jugular vein (Maquet HLS Cannula 23 Fr) and right common femoral vein (Meditronic BioMedicus Nexgen 19 Fr). Initial heparin infusion was 2000 units/hour and was continued with a target partial thromboplastin time of 50-70s.

Significant complications during ECMO treatment are outlined in Figure 1 , bleeding was managed conservatively. After 127 days on ECMO, physically and mentally stable, without J o u r n a l P r e -p r o o f signs of improvement and with single-organ failure he was accepted for LTx. This was undertaken after 138 days on ECMO. Thoraco-sternotomy was performed and veno-venous ECMO was converted to veno-arterial ECMO, by connecting both venous cannulae as venous drainage, and in addition inserting a straight arterial cannula by Seldinger technique into the ascending aorta. Bilateral lung transplantation was performed, first on the right side and then on the left without technical difficulties, and ECMO was subsequently easily weaned. Venous cannulaes were left in place for an hour in order to be able to re-start venovenous ECMO upon desaturation, and then taken out. The chest was left open due to coagulopathy and to prevent severe primary graft dysfunction (PGD) since lungs were deemed somewhat edematous. The patient was bleeding moderately postoperatively and brought back to surgery on day 2. The blood clots were removed and the chest was closed.

He remained stable and was assessed as PGD grade 1/1/0 at 24/48/72 hours, respectively.

The ventilator was weaned on postoperative day 14 and he was discharged from the Intensive care unit on day 20. Besides transient atrial fibrillation directly after intensive care discharge, further recovery was uneventful. He remained on the step-down unit until he was able to mobilize without supplemental oxygen and was then discharged to a rehabilitation facility on day 34 post lung transplant. Discharge spirometry showed a forced expiratory volume during the first second (FEV1) of 45% predicted, the bronchial anastomoses were well healed on bronchoscopy, and there was no evidence of acute rejection in transbronchial biopsies.

The most recent outpatient visit was five months post-transplant. The patient was moving freely, presented a spirometry of FEV1 of 61% predicted, and the infiltrates on plain chest xray had receded but not disappeared (figure 2), also the right phrenic palsy that can be seen at discharge x-ray had not improved. Bronchoscopy showed no signs of infection nor acute or humoral rejection. Surveillance testing for donor-specific antibodies was negative.

We report that a patient suffering from SARS-CoV-2 destroyed lungs may undergo ECMObridge-to-lung transplantation and have a good outcome even after a prolonged duration of mechanical circulatory support. The patient was awake on ECMO and able to perform physical training using bed-cycling under careful monitoring which likely contributed to the excellent result. Patients with Covid-19 have been described to undergo ECMO-bridge-to-LTx (2,3) but there is insufficient data on when to list a patient with acute respiratory distress syndrome due to COVID-19. Also, the inherent transplant dilemma with a limited donor pool provides further considerations to be made (4) . Previous data indicate that 70% of patients placed on ECMO due to Covid-19 were weaned (5) during the first wave of COVID-19.

During the second wave, this figure might be lower. Our patient initially had multiple complications and was thus ineligible for transplantation. However, the patient stabilized over time, and eventually presented a true single organ failure. It's possible that the additional complications, such as lung bleeding and pulmonary cytomegalovirus infection, hindered the healing process of our patient since he otherwise improved physically. Although this patient is not the first to have been transplanted from ECMO the patient was treated with ECMO for a longer time than previous cases. We recognize that only a small proportion of patients will be suitable for undergoing an ECMO bridge and subsequent LTx. Also, patients should not be listed for transplantation until there is a very high degree of certainty that the damage to the lungs is irreversible.

We conclude that very select patients with SARS CoV-2 destroyed lungs may undergo ECMO-bridge-to-lung transplantation and have a good outcome even after prolonged ECMO care.

J o u r n a l P r e -p r o o f 

Extracorporeal membrane oxygenation as a bridge to lung transplantation: a long-term study

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient

Lung transplantation for patients with severe COVID-19

When to consider lung transplantation for COVID-19

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry